 | • レポートコード：D0804-08948 • 出版社/出版日：GlobalInfoResearch / 2020年7月28日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、104ページ • 納品方法：Eメール • 産業分類：医薬品・治療 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、ノイラミニダーゼ阻害剤の世界市場を広く調査・分析し、今後の市場展望をまとめております。ノイラミニダーゼ阻害剤の種類別市場規模（ザナミビル、オセルタミビル、ペラミビル、ラニナミビル）、用途別市場規模（病院薬局、ドラッグストア、小売店、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：GlaxoSmithKline、BioCryst、Gilead Sciences、F. Hoffman-La Roche、Daiichi Sankyo ・地域別グローバル市場分析 2015年-2020年 ・ノイラミニダーゼ阻害剤の北米市場（アメリカ、カナダ、メキシコ） ・ノイラミニダーゼ阻害剤のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・ノイラミニダーゼ阻害剤のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・ノイラミニダーゼ阻害剤の南米市場（ブラジル、アルゼンチン） ・ノイラミニダーゼ阻害剤の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：ザナミビル、オセルタミビル、ペラミビル、ラニナミビル ・用途別分析：病院薬局、ドラッグストア、小売店、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The Neuraminidase Inhibitor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global Neuraminidase Inhibitor sales will be xx in 2020 from Neuraminidase Inhibitor million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Neuraminidase Inhibitor market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the Neuraminidase Inhibitor industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Neuraminidase Inhibitor and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
Neuraminidase Inhibitor market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Neuraminidase Inhibitor market has been segmented into
Zanamivir
Oseltamivir
Peramivir
Laninamivir
By Application, Neuraminidase Inhibitor has been segmented into:
Hospital Pharmacies
Drug Stores
Retail Stores
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Neuraminidase Inhibitor market presented in the report. This section sheds light on the sales growth of different regional and country-level Neuraminidase Inhibitor markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Neuraminidase Inhibitor market.
The report offers in-depth assessment of the growth and other aspects of the Neuraminidase Inhibitor market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Neuraminidase Inhibitor Market Share Analysis
Neuraminidase Inhibitor competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Neuraminidase Inhibitor sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Neuraminidase Inhibitor sales, revenue and market share for each player covered in this report.
The major players covered in Neuraminidase Inhibitor are:
GlaxoSmithKline
BioCryst
Gilead Sciences
F. Hoffman-La Roche
Daiichi Sankyo
Among other players domestic and global, Neuraminidase Inhibitor market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neuraminidase Inhibitor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neuraminidase Inhibitor, with price, sales, revenue and global market share of Neuraminidase Inhibitor in 2018 and 2019.
Chapter 3, the Neuraminidase Inhibitor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuraminidase Inhibitor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Neuraminidase Inhibitor market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Neuraminidase Inhibitor sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Neuraminidase Inhibitor Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neuraminidase Inhibitor Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Zanamivir
1.2.3 Oseltamivir
1.2.4 Peramivir
1.2.5 Laninamivir
1.3 Market Analysis by Application
1.3.1 Overview: Global Neuraminidase Inhibitor Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacies
1.3.3 Drug Stores
1.3.4 Retail Stores
1.3.5 Others
1.4 Overview of Global Neuraminidase Inhibitor Market
1.4.1 Global Neuraminidase Inhibitor Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
1.6 COVID-19 Outbreak: Neuraminidase Inhibitor Industry Impact
1.6.1 COVID-19 Potential Implications for the Neuraminidase Inhibitor
1.6.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Neuraminidase Inhibitor
1.6.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.6.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.6.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.6.2 Opportunity Analysis in Covid-19 Crisis
1.6.3 Market Risk and Restraints
1.6.4 Market Driving Force
2 Manufacturers Profiles
2.1 GlaxoSmithKline
2.1.1 GlaxoSmithKline Details
2.1.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 GlaxoSmithKline SWOT Analysis
2.1.4 GlaxoSmithKline Product and Services
2.1.5 GlaxoSmithKline Neuraminidase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 BioCryst
2.2.1 BioCryst Details
2.2.2 BioCryst Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 BioCryst SWOT Analysis
2.2.4 BioCryst Product and Services
2.2.5 BioCryst Neuraminidase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Gilead Sciences
2.3.1 Gilead Sciences Details
2.3.2 Gilead Sciences Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Gilead Sciences SWOT Analysis
2.3.4 Gilead Sciences Product and Services
2.3.5 Gilead Sciences Neuraminidase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 F. Hoffman-La Roche
2.4.1 F. Hoffman-La Roche Details
2.4.2 F. Hoffman-La Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 F. Hoffman-La Roche SWOT Analysis
2.4.4 F. Hoffman-La Roche Product and Services
2.4.5 F. Hoffman-La Roche Neuraminidase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Daiichi Sankyo
2.5.1 Daiichi Sankyo Details
2.5.2 Daiichi Sankyo Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Daiichi Sankyo SWOT Analysis
2.5.4 Daiichi Sankyo Product and Services
2.5.5 Daiichi Sankyo Neuraminidase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Neuraminidase Inhibitor Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Neuraminidase Inhibitor Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Neuraminidase Inhibitor Manufacturer Market Share in 2019
3.3.2 Top 6 Neuraminidase Inhibitor Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Neuraminidase Inhibitor Sales, Revenue and Market Share by Regions
4.1.1 Global Neuraminidase Inhibitor Sales and Market Share by Regions (2015-2020)
4.1.2 Global Neuraminidase Inhibitor Revenue and Market Share by Regions (2015-2020)
4.2 North America Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
4.3 Europe Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
4.5 South America Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Neuraminidase Inhibitor Sales, Revenue and Market Share by Country
5.1.1 North America Neuraminidase Inhibitor Sales and Market Share by Country (2015-2020)
5.1.2 North America Neuraminidase Inhibitor Revenue and Market Share by Country (2015-2020)
5.2 United States Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
5.3 Canada Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
5.4 Mexico Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Neuraminidase Inhibitor Sales, Revenue and Market Share by Country
6.1.1 Europe Neuraminidase Inhibitor Sales and Market Share by Country (2015-2020)
6.1.2 Europe Neuraminidase Inhibitor Revenue and Market Share by Country (2015-2020)
6.2 Germany Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
6.3 UK Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
6.4 France Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
6.5 Russia Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
6.6 Italy Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Neuraminidase Inhibitor Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Neuraminidase Inhibitor Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Neuraminidase Inhibitor Revenue and Market Share by Regions (2015-2020)
7.2 China Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
7.3 Japan Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
7.4 Korea Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
7.5 India Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
7.7 Australia Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Neuraminidase Inhibitor Sales, Revenue and Market Share by Country
8.1.1 South America Neuraminidase Inhibitor Sales and Market Share by Country (2015-2020)
8.1.2 South America Neuraminidase Inhibitor Revenue and Market Share by Country (2015-2020)
8.2 Brazil Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
8.3 Argentina Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Neuraminidase Inhibitor Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Neuraminidase Inhibitor Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Neuraminidase Inhibitor Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
9.3 Turkey Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
9.4 Egypt Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
9.5 South Africa Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Neuraminidase Inhibitor Sales and Market Share by Type (2015-2020)
10.2 Global Neuraminidase Inhibitor Revenue and Market Share by Type (2015-2020)
10.3 Global Neuraminidase Inhibitor Price by Type (2015-2020)
11 Global Neuraminidase Inhibitor Market Segment by Application
11.1 Global Neuraminidase Inhibitor Sales Market Share by Application (2015-2020)
11.2 Global Neuraminidase Inhibitor Revenue Market Share by Application (2015-2020)
11.3 Global Neuraminidase Inhibitor Price by Application (2015-2020)
12 Market Forecast
12.1 Global Neuraminidase Inhibitor Sales, Revenue and Growth Rate (2021-2025)
12.2 Neuraminidase Inhibitor Market Forecast by Regions (2021-2025)
12.2.1 North America Neuraminidase Inhibitor Market Forecast (2021-2025)
12.2.2 Europe Neuraminidase Inhibitor Market Forecast (2021-2025)
12.2.3 Asia-Pacific Neuraminidase Inhibitor Market Forecast (2021-2025)
12.2.4 South America Neuraminidase Inhibitor Market Forecast (2021-2025)
12.2.5 Middle East & Africa Neuraminidase Inhibitor Market Forecast (2021-2025)
12.3 Neuraminidase Inhibitor Market Forecast by Type (2021-2025)
12.3.1 Global Neuraminidase Inhibitor Sales Forecast by Type (2021-2025)
12.3.2 Global Neuraminidase Inhibitor Market Share Forecast by Type (2021-2025)
12.4 Neuraminidase Inhibitor Market Forecast by Application (2021-2025)
12.4.1 Global Neuraminidase Inhibitor Sales Forecast by Application (2021-2025)
12.4.2 Global Neuraminidase Inhibitor Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Neuraminidase Inhibitor Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Neuraminidase Inhibitor by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Neuraminidase Inhibitor Market Size and Growth Estimation in Various Scenarios in 2020
Table 4. Global Neuraminidase Inhibitor Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 5. Market Opportunities in Next Few Years
Table 6. Market Risks Analysis
Table 7. Market Drivers
Table 8. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 9. GlaxoSmithKline Neuraminidase Inhibitor Major Business
Table 10. GlaxoSmithKline Neuraminidase Inhibitor Total Revenue (USD Million) (2018-2019)
Table 11. GlaxoSmithKline SWOT Analysis
Table 12. GlaxoSmithKline Neuraminidase Inhibitor Product and Services
Table 13. GlaxoSmithKline Neuraminidase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 14. BioCryst Basic Information, Manufacturing Base and Competitors
Table 15. BioCryst Neuraminidase Inhibitor Major Business
Table 16. BioCryst Neuraminidase Inhibitor Total Revenue (USD Million) (2018-2019)
Table 17. BioCryst SWOT Analysis
Table 18. BioCryst Neuraminidase Inhibitor Product and Services
Table 19. BioCryst Neuraminidase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 20. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 21. Gilead Sciences Neuraminidase Inhibitor Major Business
Table 22. Gilead Sciences Neuraminidase Inhibitor Total Revenue (USD Million) (2018-2019)
Table 23. Gilead Sciences SWOT Analysis
Table 24. Gilead Sciences Neuraminidase Inhibitor Product and Services
Table 25. Gilead Sciences Neuraminidase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 26. F. Hoffman-La Roche Basic Information, Manufacturing Base and Competitors
Table 27. F. Hoffman-La Roche Neuraminidase Inhibitor Major Business
Table 28. F. Hoffman-La Roche Neuraminidase Inhibitor Total Revenue (USD Million) (2018-2019)
Table 29. F. Hoffman-La Roche SWOT Analysis
Table 30. F. Hoffman-La Roche Neuraminidase Inhibitor Product and Services
Table 31. F. Hoffman-La Roche Neuraminidase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 32. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 33. Daiichi Sankyo Neuraminidase Inhibitor Major Business
Table 34. Daiichi Sankyo Neuraminidase Inhibitor Total Revenue (USD Million) (2018-2019)
Table 35. Daiichi Sankyo SWOT Analysis
Table 36. Daiichi Sankyo Neuraminidase Inhibitor Product and Services
Table 37. Daiichi Sankyo Neuraminidase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 38. Global Neuraminidase Inhibitor Sales by Manufacturer (2018-2019) (K Units)
Table 39. Global Neuraminidase Inhibitor Revenue by Manufacturer (2018-2019) (USD Million)
Table 40. Global Neuraminidase Inhibitor Sales by Regions (2015-2020) (K Units)
Table 41. Global Neuraminidase Inhibitor Sales Market Share by Regions (2015-2020)
Table 42. Global Neuraminidase Inhibitor Revenue by Regions (2015-2020) (USD Million)
Table 43. North America Neuraminidase Inhibitor Sales by Countries (2015-2020) (K Units)
Table 44. North America Neuraminidase Inhibitor Sales Market Share by Countries (2015-2020)
Table 45. North America Neuraminidase Inhibitor Revenue by Countries (2015-2020) (USD Million)
Table 46. North America Neuraminidase Inhibitor Revenue Market Share by Countries (2015-2020)
Table 47. Europe Neuraminidase Inhibitor Sales by Countries (2015-2020) (K Units)
Table 48. Europe Neuraminidase Inhibitor Sales Market Share by Countries (2015-2020)
Table 49. Europe Neuraminidase Inhibitor Revenue by Countries (2015-2020) (USD Million)
Table 50. Asia-Pacific Neuraminidase Inhibitor Sales by Regions (2015-2020) (K Units)
Table 51. Asia-Pacific Neuraminidase Inhibitor Sales Market Share by Regions (2015-2020)
Table 52. Asia-Pacific Neuraminidase Inhibitor Revenue by Regions (2015-2020) (USD Million)
Table 53. South America Neuraminidase Inhibitor Sales by Countries (2015-2020) (K Units)
Table 54. South America Neuraminidase Inhibitor Sales Market Share by Countries (2015-2020)
Table 55. South America Neuraminidase Inhibitor Revenue by Countries (2015-2020) (USD Million)
Table 56. South America Neuraminidase Inhibitor Revenue Market Share by Countries (2015-2020)
Table 57. Middle East & Africa Neuraminidase Inhibitor Sales by Countries (2015-2020) (K Units)
Table 58. Middle East & Africa Neuraminidase Inhibitor Sales Market Share by Countries (2015-2020)
Table 59. Middle East & Africa Neuraminidase Inhibitor Revenue by Countries (2015-2020) (USD Million)
Table 60. Middle East & Africa Neuraminidase Inhibitor Revenue Market Share by Countries (2015-2020)
Table 61. Global Neuraminidase Inhibitor Sales by Type (2015-2020) (K Units)
Table 62. Global Neuraminidase Inhibitor Sales Share by Type (2015-2020)
Table 63. Global Neuraminidase Inhibitor Revenue by Type (2015-2020) (USD Million)
Table 64. Global Neuraminidase Inhibitor Revenue Share by Type (2015-2020)
Table 65. Global Neuraminidase Inhibitor Sales by Application (2015-2020) (K Units)
Table 66. Global Neuraminidase Inhibitor Sales Share by Application (2015-2020)
Table 67. Global Neuraminidase Inhibitor Sales Forecast by Regions (2021-2025) (K Units)
Table 68. Global Neuraminidase Inhibitor Market Share Forecast by Regions (2021-2025)
Table 69. Global Neuraminidase Inhibitor Sales Forecast by Type (2021-2025) (K Units)
Table 70. Global Neuraminidase Inhibitor Market Share Forecast by Type (2021-2025)
Table 71. Global Neuraminidase Inhibitor Sales Forecast by Application (2021-2025)
Table 72. Global Neuraminidase Inhibitor Market Share Forecast by Application (2021-2025)
Table 73. Direct Channel Pros & Cons
Table 74. Indirect Channel Pros & Cons
Table 75. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Neuraminidase Inhibitor Picture
Figure 2. Global Sales Market Share of Neuraminidase Inhibitor by Type in 2019
Figure 3. Zanamivir Picture
Figure 4. Oseltamivir Picture
Figure 5. Peramivir Picture
Figure 6. Laninamivir Picture
Figure 7. Neuraminidase Inhibitor Sales Market Share by Application in 2018
Figure 8. Hospital Pharmacies Picture
Figure 9. Drug Stores Picture
Figure 10. Retail Stores Picture
Figure 11. Others Picture
Figure 12. Global Neuraminidase Inhibitor Market Status and Outlook (2015-2025) (USD Million)
Figure 13. United States Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Canada Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Mexico Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Germany Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 17. France Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 18. UK Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Russia Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Italy Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 21. China Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Japan Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Korea Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 24. India Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Southeast Asia Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Australia Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 27. Brazil Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Egypt Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Saudi Arabia Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 30. South Africa Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Turkey Neuraminidase Inhibitor Revenue (Value) and Growth Rate (2015-2025)
Figure 32. Global Neuraminidase Inhibitor Sales Market Share by Manufacturer in 2019
Figure 33. Global Neuraminidase Inhibitor Revenue Market Share by Manufacturer in 2019
Figure 34. Top 3 Neuraminidase Inhibitor Manufacturer (Revenue) Market Share in 2019
Figure 35. Top 6 Neuraminidase Inhibitor Manufacturer (Revenue) Market Share in 2019
Figure 36. Key Manufacturer Market Share Trend
Figure 37. Global Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 38. Global Neuraminidase Inhibitor Revenue and Growth Rate (2015-2020) (USD Million)
Figure 39. Global Neuraminidase Inhibitor Revenue Market Share by Regions (2015-2020)
Figure 40. Global Neuraminidase Inhibitor Revenue Market Share by Regions in 2018
Figure 41. North America Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
Figure 42. Europe Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
Figure 44. South America Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
Figure 45. Middle East & Africa Neuraminidase Inhibitor Sales and Growth Rate (2015-2020)
Figure 46. North America Neuraminidase Inhibitor Revenue and Growth Rate (2015-2020) (USD Million)
Figure 47. North America Neuraminidase Inhibitor Sales Market Share by Countries (2015-2020)
Figure 48. North America Neuraminidase Inhibitor Sales Market Share by Countries in 2018
Figure 49. North America Neuraminidase Inhibitor Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 50. North America Neuraminidase Inhibitor Revenue Market Share by Countries in 2018
Figure 51. United States Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 52. Canada Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 53. Mexico Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 54. Europe Neuraminidase Inhibitor Revenue and Growth Rate (2015-2020) (USD Million)
Figure 55. Europe Neuraminidase Inhibitor Revenue Market Share by Countries (2015-2020)
Figure 56. Europe Neuraminidase Inhibitor Revenue Market Share by Countries in 2019
Figure 57. Germany Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 58. UK Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 59. France Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 60. Russia Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 61. Italy Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 62. Asia-Pacific Neuraminidase Inhibitor Revenue and Growth Rate (2015-2020) (USD Million)
Figure 63. Asia-Pacific Neuraminidase Inhibitor Sales Market Share by Regions 2019
Figure 64. Asia-Pacific Neuraminidase Inhibitor Revenue Market Share by Regions 2019
Figure 65. China Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 66. Japan Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 67. Korea Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 68. India Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 69. Southeast Asia Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 70. South America Neuraminidase Inhibitor Revenue and Growth Rate (2015-2020) (USD Million)
Figure 71. South America Neuraminidase Inhibitor Sales Market Share by Countries in 2019
Figure 72. South America Neuraminidase Inhibitor Revenue Market Share by Countries in 2019
Figure 73. Brazil Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 74. Argentina Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 75. Middle East and Africa Neuraminidase Inhibitor Revenue and Growth Rate (2015-2020) (USD Million)
Figure 76. Middle East and Africa Neuraminidase Inhibitor Sales Market Share by Countries in 2019
Figure 77. Middle East and Africa Neuraminidase Inhibitor Revenue Market Share by Countries (2015-2020)
Figure 78. Middle East and Africa Neuraminidase Inhibitor Revenue Market Share by Countries in 2019
Figure 79. Saudi Arabia Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 80. Egypt Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 81. Turkey Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 82. South Africa Neuraminidase Inhibitor Sales and Growth Rate (2015-2020) (K Units)
Figure 83. Global Neuraminidase Inhibitor Sales and Growth Rate (2021-2025) (K Units)
Figure 84. Global Neuraminidase Inhibitor Revenue and Growth Rate (2021-2025) (USD Million)
Figure 85. North America Sales Neuraminidase Inhibitor Market Forecast (2021-2025) (K Units)
Figure 86. Europe Sales Neuraminidase Inhibitor Market Forecast (2021-2025) (K Units)
Figure 87. Asia-Pacific Sales Neuraminidase Inhibitor Market Forecast (2021-2025) (K Units)
Figure 88. South America Sales Neuraminidase Inhibitor Market Forecast (2021-2025) (K Units)
Figure 89. Middle East & Africa Sales Neuraminidase Inhibitor Market Forecast (2021-2025) (K Units)
Figure 90. Sales Channel: Direct Channel vs Indirect Channel
酵素ポリADPリボースポリメラーゼ阻害剤の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Enzyme Poly ADP Ribose Polymerase Inhibitor market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The E…- 酵素ポリADPリボースポリメラーゼ（PARP）阻害剤の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Enzyme Poly ADP Ribose Polymerase (PARP) Inhibitor market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019…
- シクロオキシゲナーゼ2阻害剤の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Cyclooxygenase 2 Inhibitor market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Cyclooxygenase 2 I…
- VEGF阻害薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The VEGF Inhibitor Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, …
- シクロオキシゲナーゼ2阻害剤（新型コロナウイルス）の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The Cyclooxygenase 2 Inhibitor（COVID-19) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chai…